Martin Tolar, M.D., Ph.D.

Form D signer

Martin Tolar, M.D., Ph.D.

President and Chief Executive Officer at Alzheon

Form D signer

Capital raised by Alzheon

$126.3M+$126.3M latest round

1 Form D filing · first filed Feb 2024 · Framingham, MA

CURRENT ROLE: President and Chief Executive Officer
SECTOR: Biotech
COMPANY FILINGS: 1
TEAM ON FILE: 2
FOUNDED: —
30D INTEREST: 1 ↗

Career

1 company on file

AlzheonBiotech · Framingham, MAsince Feb 2024

President and Chief Executive Officer

Signatory on Alzheon's Form D filings · $126.3M raised across 1

Company filings

via EDGAR · Form D for Alzheon1

DateCompanyFormAmountRole on filing

Feb 27, 2024AlzheonForm D/A+$126.3MPresident and Chief Executive Officer

Form D/AFeb 27, 2024 · Alzheon+$126.3Mas President and Chief Executive Officer

Overview

Last filing Feb 27, 2024

Martin Tolar, M.D., Ph.D. is on file as President and Chief Executive Officer at Alzheon in Framingham, MA. Alzheon has 1 Form D filing on record, $126.3M raised in total. Martin Tolar, M.D., Ph.D. appears as a signatory on the company's filings.

Teammates

Alzheon · 1

Muneer SatterDirector

Products

Alzheon · 1

ALZ-801/valiltramiprosateAlzheimer's treatment

ALZ-801/valiltramiprosate is an oral small molecule inhibitor designed to target the neurotoxic amyloid oligomers, which are believed to play a key role in the development and progression of Alzheimer's disease.